High-dose semaglutide trial: better results or just more side effects?

What did @drkarlnadolsky actually say?

Here is the uncomfortable truth: the transcript for this video is not a medical commentary. It reads like a song, a phone number, and what appears to be someone calling out to a child named Dante. There is no coherent clinical claim to extract from the spoken words. The caption, however, is a different story. It summarizes a phase 2 trial on high-dose semaglutide in people with obesity and type 2 diabetes, noting "modest additional sugar-lowering effect, with additional weight loss, at the expense of more side effects and treatment discontinuations." That caption language is what we can actually assess. The video appears to be a case of content that either failed to upload correctly or was mislabeled. We are fact-checking the caption claims, because that is where the substance lives.

Does the science back this up?

The caption's summary is largely accurate and appropriately restrained. The study linked is a real phase 2 dose-escalation trial published in Diabetes Care (Davies et al., 2025, Diabetes Care), examining semaglutide doses up to 7.2 mg weekly, well above the 2.4 mg weekly ceiling used in Wegovy. Across higher dose arms, participants did see additional HbA1c reductions and body weight reductions compared to the approved 2.4 mg dose, but the incremental glycemic benefit was modest. Gastrointestinal side effects, particularly nausea and vomiting, were meaningfully more frequent at higher doses. Discontinuation rates climbed as the dose went up. The caption captures this tradeoff honestly. It does not oversell the efficacy signal or downplay the tolerability problem. That is worth crediting.

• HbA1c reductions were statistically significant but the absolute additional benefit over 2.4 mg was small.
• Weight loss did increase at higher doses, which is the more commercially interesting finding.
• GI adverse events and discontinuations increased in a dose-dependent pattern.

What did they get wrong (or right)?

The caption gets the broad strokes right. Calling the sugar-lowering effect "modest" is accurate and honest, which is not a given in GLP-1 content on social media. Many creators in this space would have led with the weight loss number and buried the side effect data. The framing here is balanced. What is missing is any quantification. How much additional weight loss are we talking about? The trial data suggests roughly 3 to 5 additional percentage points of body weight loss at the highest doses compared to 2.4 mg, but without that context, a viewer cannot judge whether the added risk is worth it. The caption also does not clarify this is a phase 2 trial, meaning it is a relatively small, early-stage study not powered for long-term safety or cardiovascular outcomes. Readers deserve that caveat explicitly stated.

What should you actually know?

Phase 2 trials are hypothesis-generating, not practice-changing. The fact that higher semaglutide doses produce more weight loss is not surprising given the drug's dose-response relationship, but "more weight loss" does not automatically mean "better treatment." Tolerability is a legitimate clinical outcome. A drug that causes enough nausea and vomiting to make patients quit is not a better drug, it is just a higher dose. The FDA-approved ceiling for semaglutide in obesity is 2.4 mg weekly for a reason. No phase 3 data yet exists to support routine use of 7.2 mg weekly, and no prescriber should be extrapolating these phase 2 findings into practice today. If you are on semaglutide and wondering whether a higher dose would help you more, that is a conversation for your prescribing clinician, not a TikTok comment section.

• Compounded semaglutide is not equivalent to FDA-approved Ozempic or Wegovy, regardless of stated dose.
• Higher doses in this trial were not tested for long-term cardiovascular or renal outcomes.
• Discontinuation rates in the highest dose arms are a clinically meaningful red flag that deserves equal weight alongside efficacy numbers.